Linden J, Thai T, Figler H, Jin X, Robeva A S
Department of Internal Medicine, University of Virginia, Charlottesville, Virginia, USA.
Mol Pharmacol. 1999 Oct;56(4):705-13.
Recombinant human A(2B) adenosine receptors (A(2B)ARs) and receptors extended on the amino terminus with hexahistidine and the FLAG epitope, DYKDDDDK (H/F-A(2B)) were stably overexpressed (to >20,000 fmol/mg protein) in human embryonic kidney 293 cells (HEK-A(2B)). By Western blotting, the H/F-A(2B) receptor runs as a 34.8-kDa glycoprotein. Pharmacological properties of A(2B)ARs were characterized with (125)I-3-aminobenzyl-8-phenyl-(4-oxyacetic acid)-1-propylxanthine (K(D), 36 nM). In competition binding assays, the affinity of agonists is reduced by substitution on either the N(6)- or the C-2 position of the adenine ring, whereas 5'-substitutions increase affinity, resulting in the potency order: 5'-N-ethylcarboxamidoadenosine (NECA) >> N(6)-aminobenzyl-NECA approximately 2-chloroadenosine > 2-[4-(2-carboxyethyl)phenethylamino]-NECA (CGS21680) > N(6)-aminobenzyladenosine. The A(2B)AR is potently blocked by the A(2A)-selective antagonist 4-(2-[7-amino-2-[2-furyl][1,2, 4]triazolo-[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol (ZM241385; K(I), 32 nM for A(2B), 1.4 nM for A(2A)) and the A(1) selective antagonist 8-cyclopentyl-1,3-dipropylxanthine (K(I), 50.5 nM for A(2B); 2.5 nM for A(1)). The K(I) values for the antiasthmatic xanthines, theophylline (7.8 microM) and enprofylline (6.4 microM), are below their therapeutic plasma concentrations (20 to 50 microM), and agree with K(I) determinations for inhibition of NECA-stimulated cAMP accumulation in HEK-A(2B) cells. NECA or N(6)-(2-iodo)benzyl-5'-N-methylcarboxamidodoadenosine (IB-MECA) stimulate inositol trisphosphates and calcium accumulation in HEK-A(2B) or HEK-A(3) cells, respectively, but only the A(3) response is prevented by pertussis toxin. In human HMC-1 mast cells, A(2B)AR activation stimulates calcium mobilization and cAMP accumulation. We conclude that HEK-A(2B) cells and HMC-1 mast cells possess A(2B)AR glycoproteins that are coupled to both G(q/11) and G(s).
重组人A(2B)腺苷受体(A(2B)ARs)以及在氨基末端延伸有六组氨酸和FLAG表位(DYKDDDDK,即H/F-A(2B))的受体在人胚肾293细胞(HEK-A(2B))中稳定过表达(至>20,000 fmol/mg蛋白)。通过蛋白质印迹法,H/F-A(2B)受体以34.8 kDa糖蛋白形式迁移。A(2B)ARs的药理学特性用(125)I-3-氨基苄基-8-苯基-(4-氧代乙酸)-1-丙基黄嘌呤(K(D),36 nM)进行表征。在竞争结合试验中,激动剂的亲和力因腺嘌呤环的N(6)-或C-2位被取代而降低,而5'-位取代则增加亲和力,导致效价顺序为:5'-N-乙基甲酰胺基腺苷(NECA)>> N(6)-氨基苄基-NECA≈2-氯腺苷> 2-[4-(2-羧乙基)苯乙氨基]-NECA(CGS21680)> N(6)-氨基苄基腺苷。A(2B)AR被A(2A)选择性拮抗剂4-(2-[7-氨基-2-[2-呋喃基][1,2,4]三唑并-[2,3-a][1,3,5]三嗪-5-基-氨基]乙基)苯酚(ZM241385;对A(2B)的K(I)为32 nM,对A(2A)为1.4 nM)和A(1)选择性拮抗剂8-环戊基-1,3-二丙基黄嘌呤(对A(2B)的K(I)为50.5 nM;对A(1)为2.5 nM)有效阻断。抗哮喘黄嘌呤类药物茶碱(7.8 μM)和恩丙茶碱(6.4 μM)的K(I)值低于其治疗血浆浓度(20至50 μM),并且与抑制HEK-A(2B)细胞中NECA刺激的cAMP积累的K(I)测定结果一致。NECA或N(6)-(2-碘)苄基-5'-N-甲基甲酰胺基腺苷(IB-MECA)分别刺激HEK-A(2B)或HEK-A(3)细胞中的肌醇三磷酸和钙积累,但只有A(3)反应被百日咳毒素阻断。在人HMC-1肥大细胞中,A(2B)AR激活刺激钙动员和cAMP积累。我们得出结论,HEK-A(2B)细胞和HMC-1肥大细胞拥有与G(q/11)和G(s)均偶联的A(2B)AR糖蛋白。